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Genetic susceptibility and environmental factors 
are responsible for the development of systemic 
lupus erythematosus (SLE). Mouse models of 
SLE, in particular, have provided signifi  cant 
insights into the identifi  cation of critical check-
points and the molecular pathways that medi-
ate the generation of this autoimmune disease 
(1–12). These models have demonstrated that 
the loss of tolerance that initiates SLE results 
from the accumulated eff  ect of multiple genetic 
defects, which culminates in the deposition of 
pathogenic IgG autoantibodies in end-organs 
such as the kidney, where they induce infl  am-
mation resulting in pathological events (6). IgG 
anti-DNA autoantibodies are a general feature 
of lupus and the molecular mechanisms that 
  result in the selection and expansion of anti-
DNA autoantibodies have been suggested to 
involve the Toll-like receptors (TLRs). In 
particular, TLR9 and its signaling molecule 
MyD88 can provide a costimulatory signal in 
vitro for B cell stimulation by DNA (13, 14). 
The DNA ligand for TLR9 may be provided 
in vivo by apoptotic bodies that are incom-
pletely cleared in lupus and could thus lead to 
uncontrolled activation of the TLR9–MyD88 
pathway and promote anti-DNA autoantibody 
generation (13–15).
It has recently been shown that pediatric 
SLE patients have a failure to establish B cell 
tolerance early during B cell development, 
leading to increased numbers of antinuclear, 
anticytoplasmic, and polyreactive cells in the 
naive peripheral B cell pool (16, 17). The in-
creased frequency of autoreactive, naive B 
cells is thus suggested to be a prerequisite for 
the generation of autoantibodies and the de-
velopment of lupus (17). A similar situation 
has been discussed in murine models of SLE 
with polyreactive autoantibodies deposited in 
the kidneys of these mice (18, 19). These poly-
reactive antibodies recognize DNA as well as 
glomerular antigens (18, 19) and are believed 
to be responsible for inducing proteinurea 
and thereby contribute to the pathology of 
SLE (19).
We have recently described a strain-specifi  c 
SLE model in which loss of the IgG inhibitory 
Fcγ receptor RIIB molecule on the C57BL/6 
background resulted in the accumulation of 
pathogenic autoantibodies in the kidney with 
the development of glomerulonephritis and 
premature mortality (2). Through the use of 
a B cell–intrinsic, anti-DNA knockin model 
(the 56R VDJ4 heavy chain transgene on 
the C57BL/6 background), we have shown 
that the C57BL/6 strain provided a suscep-
tible background by virtue of its inability to  The online version of this article contains supplemental material. The online version of this article contains supplemental material.
<doi>10.1084/jem.20052438</doi><aid>20052438</aid>TLR9/MyD88 signaling is required 
for class switching to pathogenic 
IgG2a and 2b autoantibodies in SLE
Marc Ehlers,1 Hidehiro Fukuyama,1 Tracy L. McGaha,1 Alan Aderem,2 
and Jeff  rey V . Ravetch1
1Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10021
2The Institute for Systems Biology, Seattle, WA 98103
Loss of tolerance in systemic lupus erythematosus (SLE) leads to the generation of auto-
antibodies, which accumulate in end-organs where they induce disease. Here we show that 
immunoglobulin (Ig)G2a and 2b autoantibodies are the pathogenic isotypes by recruiting 
Fc𝗄RIV expressing macrophages. Class switching, but not development, of IgM anti-self B 
cells to these pathogenic subclasses requires the innate immune receptor Toll-like receptor 
(TLR)9 and MyD88 signaling. In their absence, switching of autoreactive B cells to the 
IgG2a and 2b subclasses is blocked, resulting in reduced pathology and mortality. In con-
trast, switching of anti-self B cells to IgG1 is not perturbed and generation of nonautore-
active IgG2a and 2b antibodies is not impaired in TLR9-defi  cient mice. Thus, the TLR9 
pathway is a potential target for therapeutic intervention in SLE.
CORRESPONDENCE
Jeffrey V. Ravetch: 
ravetch@rockefeller.edu
Abbreviations used: GBM, anti-
glomerular basement membrane; 
GC, germinal center; SLE, 
  systemic lupus erythematosus; 
TLR, Toll-like receptor.
CORRESPONDENCE
Jeffrey V. Ravetch: 
ravetch@rockefeller.edu
Abbreviations used: GBM, anti-
glomerular basement membrane; 
GC, germinal center; SLE, 
  systemic lupus erythematosus; 
TLR, Toll-like receptor.554  TLR/MYD88 REQUIREMENT FOR PATHOGENIC IGG2 IN MURINE SLE | Ehlers et al.
  completely edit the light chain repertoire associating with the 
56R heavy chain, thus allowing for the emergence of anti-
DNA B cells into the periphery (6).   Although these mice 
developed circulating anti-DNA antibodies of the IgM iso-
type, they did not develop disease, consistent with previous 
observations in which IgG autoantibodies were frequently 
associated with disease in SLE models (6). Combining the 
56R+.B6 mice with the FcγRIIB defi  ciency was suffi   cient 
to result in the accumulation of pathogenic IgG antibodies by 
permitting the expansion of anti-DNA IgG plasma cells with 
subsequent tissue deposition of autoantibodies in the glomer-
uli and glomerulonephritis (6).
Using these lupus models, we have examined the con-
tribution of the TLR9/MyD88 pathway to the generation 
of anti-DNA/polyreactive autoantibodies and have observed 
a crucial role for these pathways in the class switching of 
anti-DNA–expressing B cells to the pathogenic IgG2a and 
2b subclasses. The loss of TLR9 protected lupus-susceptible 
mice from the spontaneous development of these pathogenic 
anti-DNA subclasses, while not aff  ecting the ability to class 
switch to exogenous antigens. The specifi  city of the TLR9–
MyD88 pathway to regulating a B cell–intrinsic, anti-DNA 
class switch to IgG2a and 2b is likely the result of the ability 
of this pathway to induce the transcription factor T-bet in 
B cells.
RESULTS
Pathogenic IgG subclasses in SLE
To determine if specifi  c IgG subclasses were responsible for 
the pathological manifestations of the autoimmune disease in 
FcγRIIB−/−.B6 mice, we analyzed the IgG subclasses of the 
autoantibodies in the serum and IgG subclasses deposited in 
the kidneys of these mice (Fig. 1, A and B). IgG autoanti-
bodies in the serum as well as IgG depositions in the kidney 
of these mice were mainly of the IgG2a and IgG2b sub-
classes. IgG1 and IgG3 autoantibodies were underrepre-
sented. IgG depositions were undetectable in wt.B6 mice 
(unpublished data). The observation that these subclasses 
dominated in this systemic autoimmune disease suggested a 
mechanism that could account for the severity of tissue 
Figure 1.  MyD88 defi  ciency protected against generation and 
deposition of pathogenic IgG2a and 2b autoantibodies and SLE. 
(A) IgG subclass analysis of autoantibodies in the serum of 5-mo-old wt.
B6 (n = 4), FcγRIIB−/−MyD88+/−.B6 (n = 8), and FcγRIIB−/−MyD88−/−.B6 
(n = 6) mice. Shown are anti-DNA and antinuclear antigen titers as 
  determined by ANA ELISA. IgG2ab (haplotype: b) and 2b autoantibodies 
were up-regulated in FcγRIIB−/−MyD88+/−.B6 mice compared with wt.B6 
mice (P = 0.02 and P = 0.004, respectively), whereas IgG2a and 2b titers 
were reduced to baseline in the absent of MyD88 (P = 0.02 and 0.004, 
respectively). Horizontal bars represent the average. (B) Histological and 
immunofl  uorescence analysis of kidney sections of 9.5-mo-old mice 
stained with hematoxylin and eosin (H+E) or with anti–mouse IgG sub-
classes. Compared with the FcγRIIB−/−MyD88+/−.B6 mice, FcγRIIB−/−
MyD88−/−.B6 mice showed no IgG2ab and 2b immune complex deposi-
tion and pathology in the kidney. (C) Kidney sections in B were costained 
with anti–mouse IgG2b and anti-FcγRIV (reference 20) or with Mac-I. 
Sections are representative of three independent mice from each group. 
(D) Kaplan-Meier survival curves for FcγRIIB−/−MyD88+/+ or FcγRIIB−/−.
B6 mice.JEM VOL. 203, March 20, 2006  555
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  destruction observed in this model. IgG2a and 2b are the 
most pathogenic subclasses in vivo by virtue of their unique 
ability to engage the recently described activation Fcγ recep-
tor FcγIV (20). In contrast, IgG1 antibodies are signifi  cantly 
less pathogenic, resulting from their preferential engagement 
of the inhibitory FcγRIIB molecule (20). FcγRIV-expressing 
macrophages accumulated in the kidneys of FcγRIIB−/−.B6 
mice, but not in the kidneys of wt.B6 mice (Fig. 1 C and not 
depicted) and are likely to have induced the kidney pathol-
ogy in SLE.
In addition to the anti-DNA antibodies that accumulated 
in the FcγRIIB−/−.B6 background, we detected IgG2a and 
2b subclass–restricted autoantibodies in the serum capable of 
recognizing both cardiolipin and glomerular basement mem-
brane antigens (Fig. 2). Preabsorbing the serum with glomer-
ular basement membrane (GBM) and cardiolipin antigens 
reduced the level of autoantibodies recognizing DNA, sug-
gesting that at least a component of the subclass-restricted 
autoantibodies were polyreactive (Fig. 2).
MyD88 defi  ciency protected against class switching 
to pathogenic IgG2a and 2b anti-DNA/polyreactive 
autoantibodies in SLE
We further investigated the molecular basis for the selective 
switching of autoantibodies to the pathogenic IgG2a and 2b 
subclasses by focusing on the role of the TLR–MyD88 path-
ways. Because the MyD88 pathway had been shown, in 
  vitro, to provide a costimulatory signal for B cell stimulation 
by DNA (13, 15) as well as potentially infl  uence IgG class 
switching (21), we examined its in vivo role in the defi  ned 
models of murine lupus we have established. To determine 
whether the MyD88 pathway contributed to the pathogene-
sis of a spontaneous lupus-like autoimmune disease, we gen-
erated the FcγRIIB−/−MyD88−/−.B6 strain and compared 
autoantibody production and disease progression for this 
strain in comparison with the parental FcγRIIB−/−.B6 strain. 
MyD88 defi  ciency resulted in the abrogation of IgG2a and 
2b polyreactive anti-DNA and anti-GBM and anticardiolipin 
autoantibodies (Fig. 1 A and Fig. 2). Susceptible mice lacking 
MyD88 did not demonstrate evidence of antibody deposition 
or tissue injury (Fig. 1, B and C) and were protected from 
renal disease, as measured by accumulation of blood urea 
  nitrogen (not depicted). In contrast with the parental 
FcγRIIB−/−.B6 strain, the FcγRIIB−/−MyD88−/−.B6 strain 
was protected from the premature mortality associated with 
FcγRIIB−/−.B6 mice (2) and all animals survived beyond 
9 mo of age (Fig. 1 D).
Because MyD88 is common to many toll signaling path-
ways and is expressed in myeloid, lymphoid, and dendritic 
cell types (and to determine the contribution of specifi  c TLRs 
and cell types to the protection seen in MyD88-defi  cient 
FcγRIIB−/−.B6 mice), we turned to a spontaneous lupus 
model in which the development of autoimmunity is driven 
by intrinsic B cell defects, the anti-DNA knockin model 
56R+FcγRIIB−/−.B6 (6, 22, 23). These mice already de-
velop autoantibodies after 5 wk. The triple transgenic strain 
56R+FcγRIIB−/−MyD88−/−.B6 was thus compared with its 
heterozygous counterpart for the development of autoanti-
bodies. As was the case with the FcγRIIB−/−.B6 model, de-
fi  ciency of MyD88 resulted in strong reduction of IgG 
autoantibodies in the serum of these mice (Fig. 3 A). In con-
trast, IgM anti-DNA titers derived from the 56R transgene 
(6) were only partially reduced in the MyD88-defi  cient mice 
(Fig. 3, A). Among the autoreactive IgG subclasses and IgG1 
was unaff  ected by the absence of MyD88, whereas IgG2a and 
2b were reduced to background levels (Fig. 3 A).
The point at which the MyD88 pathway was required for 
development of anti-DNA antibodies of the IgG2a and 2b 
subclasses was investigated by FACS and single cell PCR 
analysis on B cells sorted for their state of maturation from 
MyD88-defi  cient and -suffi   cient backgrounds. We found no 
diff  erences in B cell development or survival (Fig. 3, B–E and 
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20052438/DC1). A high and equivalent percentage of 
heavy chains in immature and naive B cells expressed the anti-
DNA 56R VDJ4H transgene and showed comparable editor 
Figure 2.  MyD88 defi  ciency protected against generation of IgG2a 
and 2b polyreactive autoantibodies. IgG2ab and 2b analysis of autoan-
tibodies in the serum of 5-mo-old wt.B6 (n = 4), FcγRIIB−/−MyD88+/−.B6 
(n = 8), and FcγRIIB−/−MyD88−/−.B6 (n = 6) mice. Shown are antiglo-
merular basement membrane (GBM) (A), anticardiolipin (Cardiol.) (B), and 
anti-DNA (C) titers as determined by ELISA. Polyreactivity was analyzed by 
preabsorbing the samples on the indicated ELISA plates; G: GBM; C: car-
diolipin; G,C: GBM + cardiolipin. IgG1 and IgG3 titers were not signifi  -
cantly elevated over baseline (not depicted).  Horizontal bars represent 
the average.556  TLR/MYD88 REQUIREMENT FOR PATHOGENIC IGG2 IN MURINE SLE | Ehlers et al.
light chain usage in both MyD88-suffi   cient and -  defi  cient 
animals (Fig. 3 and Fig. S1). In contrast, IgG2a and 2b 
switched heavy chains with the anti-DNA 56R VDJ4H trans-
gene could not be detected in either germinal center (GC) 
(Fig. 3 F) or splenic plasma cells (Fig. 3 G) isolated from the 
MyD88-defi   cient strain. Switching to the IgG2a and 2b 
  subclasses was restricted to the endogenous alleles in the 
MyD88-defi  cient strain. The selective abrogation of the anti-
DNA response in the MyD88-defi  cient 56R+FcγRIIB−/−.
B6 strain was consistent with a failure of anti-self antibodies 
to switch to the IgG2a and 2b subclasses.
The loss of IgG2a and 2b autoantibodies 
in MyD88-defi  cient mice is a B cell–intrinsic defect
To confi  rm that the specifi  c reduction in IgG2a and 2b auto-
antibody titers in MyD88-defi  cient mice resulted from a de-
fect of B cells to class switch to these specifi  c subclasses, we 
examined the ability of 56R-expressing naive IgM+ B cells 
to class switch to IgG subclasses in vitro (Fig. 4). Consistent 
with previous reports (21, 24), we observed that stimulation 
of MyD88+/− B cells with the TLR9 ligand CpG together 
with the B cell stimuli anti-CD40 and IL-4 resulted in the 
secretion of IgM and IgG antibodies (Fig. 4). In contrast, 
MyD88−/− B cells were specifi  cally defective in their ability 
to secrete IgG2a and 2b antibodies, whereas IgM secretion 
was unchanged and IgG1 secretion even increased (Fig. 4), 
thus indicating a cell intrinsic specifi  c defect in the ability of 
MyD88-defi  cient B cells to class switch to the IgG2a and 2b 
subclasses (25).
Figure 3.  IgG2a and IgG2b anti-DNA autoantibodies were absent 
in the germinal center and plasma cell compartments of MyD88-
defi  cient mice. (A) Isotype and subclass analysis of anti-DNA autoanti-
bodies in the serum of 7–11-wk-old wt.B6 (n = 3), 56R+RIIB−/−MyD88+/− 
(n = 4), and 56R+RIIB−/−MyD88−/−.B6 (n = 5) mice as determined by 
ANA ELISA. IgG2aa (haplotype: a) and 2b autoantibodies were strongly and 
IgG1 slightly up-regulated in 56R+FcγRIIB−/−MyD88+/−.B6 mice com-
pared with wt.B6 mice (P = 0.002, P = 0.004, and P = 0.02, respectively). 
IgG2ab autoantibodies of B cells without 56R+ were only slightly up-
regulated until 7–11 wk in 56R+FcγRIIB−/−MyD88+/−.B6 mice. Among the 
autoreactive IgG subclasses, IgG1 was unaffected by the absence of 
MyD88, whereas IgG2a and 2b titers were reduced to baseline (P = 0.002 
and 0.03, respectively). Horizontal bars represent the average. (B) MyD-
defi  cient and -suffi  cient naive splenic B cells used the same light chains, 
resulting in retention of DNA binding by the 56R VDJ4 heavy chain. Single 
IgMa
+ splenic B cells were sorted and single cell PCR was used to identify 
56R VH positive cells (knockin allele haplotype: IgMa; C57BL/6 allele haplo-
type: IgMb). These cells were further analyzed for 21D and 38C κ light 
chain usage by single cell PCR (reference 6). Naive 56R B cells using the 
21D light chain show no DNA binding, whereas 56R B cells using the 38C 
light chain can still bind DNA (reference 6). (C) Schematic presentation of 
the anti-DNA 56R knockin VDJ4H transgene. The 56R knockin VDJ4H has 
replaced the endogenous Js, can be secondarily rearranged with other 
endogenous Vs, and can class switch to all Ig isotypes (references 22, 23). 
All 56R+ mice had only one knockin allele. (D and E) MyD88-suffi  cient 
(56R+RIIB−/−MyD88+/−) and -defi  cient IgMa
+ immature bone marrow 
(BM) and naive splenic B cells retained the intact 56R VDJ4H transgene. 
Single IgMa
+ cells were sorted and analyzed by single cell PCR using a 
random VH forward primer (reference 34) and an IgM constant region 
reverse primer (reference 34). (F and G) IgG2a and 2b positive MyD88-
defi  cient GC and splenic plasma cells used the endogenous allele, whereas 
a fraction of the MyD88-suffi  cient mice (56R+RIIB−/−MyD88+/− and +/+) 
still expressed the intact 56R VDJ4H transgene. Single GL7+FAS+ GC or 
CD138high plasma cells were sorted and analyzed by single cell PCR using 
a random VH forward primer (reference 34) and specifi  c reverse primers 
for the different IgG subclass constant regions. A fraction of 56R+RIIB−/−
MyD88−/− IgG1 positive GC and plasma cells retained the intact 56R VDJ4 
heavy chain (not depicted). No IgG3 cells were found in the GC compart-
ment and no 56R+RIIB−/−MyD88+/− or −/− IgG3 positive plasma cells 
showed the intact 56R VDJ4 heavy chain (not depicted). The number of 
cells analyzed is indicated in the center of each pie graph.JEM VOL. 203, March 20, 2006  557
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TLR9 defi  ciency abrogated class switching to pathogenic 
IgG2a and 2b anti-DNA/polyreactive autoantibodies
The toll receptor mainly responsible for the abrogation of 
IgG2a and IgG2b anti-DNA antibodies was TLR9 because 
defi  ciency in this receptor largely recapitulated the reduc-
tion of IgG2a and 2b anti-DNA autoantibodies observed for 
MyD88 defi  ciency on the susceptible 56R+FcγRIIB−/−.B6 
background as shown in Fig. 5. The TLR9 pathway was 
therefore required for the generation of specifi  c anti-DNA 
IgG2a and 2b subclasses by providing a costimulatory signal 
for B cell stimulation by DNA (13). Recently, it has been 
suggested that TLR9 defi  ciency abrogates anti-DNA anti-
bodies, but not other autoantibodies, and does not protect 
from disease in another SLE mouse model (14). In contrast 
with those results, we observed that not only IgG2a and 2b 
anti-DNA autoantibodies but also anti-GBM and anticardio-
lipin autoantibodies of the IgG2a and 2b subclasses were re-
duced in 56R+FcγRIIB−/−TLR9−/−.B6 mice as compared 
with 56R+FcγRIIB−/−TLR9+/+ and +/−.B6 mice (Fig. 5). 
Preabsorbing the serum of 56R.FcγRIIB−/−.B6 mice with 
GBM and cardiolipin antigens reduced the amount of auto-
antibodies that recognized DNA suggested that at least a 
component of the autoantibodies was polyreactive in the 
56R.FcγRIIB−/−B6 mice (Fig. 5 E) and that TLR9 defi  -
ciency reduced polyreactive IgG2a and 2b autoantibodies.
FACS and single cell PCR analysis of B cells showed 
that a high and equivalent percentage of heavy chains in 
naive B cells expressed the anti-DNA 56R VDJ4H trans-
gene in TLR9-defi  cient animals (Fig. 5 F [compare with 
Fig. 3] and not depicted). In contrast, IgG2a and 2b switched 
heavy chains with the 56R VDJ4H transgene could not be 
detected in either splenic GCs or plasma cells isolated from 
the TLR9-defi   cient strain (Fig. 5 F). Switching to the 
IgG2a and 2b subclasses was restricted to the endogenous 
or secondarily rearranged knockin allele in the TLR9-
  defi  cient strain.
No evidence of kidney pathology was observed in the 
56R+FcγRIIB−/−TLR9−/−.B6 mice and all mice survived 
beyond 8 mo of age in contrast with the premature mortality 
observed for 56R+FcγRIIB−/−TLR9+/+ (unpublished data 
and reference 6). Thus, TLR9 defi  ciency protected from pa-
thology by inhibiting the generation of IgG2a and 2b polyre-
active autoantibodies.
The loss of IgG2a and 2b autoantibodies in TLR9-defi  cient 
mice is also a B cell–autonomous defect
To confi  rm that the specifi  c reduction in IgG2a and 2b auto-
antibody titers in TLR9-defi  cient mice resulted from a defect 
of B cells, we examined the ability of 56R-expressing naive 
IgM B cells to class switch to IgG subclasses in vitro (Fig. 6 A). 
As was observed for MyD88−/− B cells (Fig. 4), TLR9−/− 
B cells were specifi  cally defective in their ability to secrete 
IgG2a, 2b, and 3 antibodies in response to CpG, anti-CD40, 
and IL-4, whereas IgM secretion was unchanged and IgG1 
secretion increased (Fig. 6 A), thus indicating a cell-auto-
nomous specifi  c defect in the ability of TLR9-defi  cient B 
cells to class switch to the IgG2a, 2b, and 3 subclasses.
The selective defect in in vitro class switching of TLR9 
and MyD88-defi  cient B cells, with increased IgG1 and de-
creased IgG2a and 2b, has also been observed in B cells iso-
lated from mice defi  cient in the transcription factor T-bet 
(26). CpG has been shown in vitro to up-regulate T-bet ex-
pression in B cells in a TLR9–MyD88-dependent pathway 
(24). Our results suggested that one mechanism by which the 
TLR9–MyD88 pathway was specifi  cally regulating the IgG2a 
and 2b anti-DNA/polyreactive autoantibody response could 
be through T-bet regulation. To determine if T-bet was in-
duced in B cells isolated from the 56R+RIIB−/−TLR9+/− or 
−/− strains, we examined the levels of T-bet transcripts in B 
cells derived from these two strains upon stimulation with 
CpG, anti-CD40, and IL-4. T-bet expression was ninefold 
higher in B cells derived from the 56R+RIIB−/−TLR9+/−.B6 
strain compared with B cells derived from the 56R+RIIB−/−
TLR9−/−.B6 strain (Fig. 6 B). Therefore, absence of TLR9 
signaling resulted in less T-bet transcription (24, 26). Given 
the ability of T-bet to induce class switching in a B cell auton-
omous mechanism (26), our results suggest that this pathway 
is a likely route for TLR9–MyD88 regulation of autoanti-
body class switching in vivo as well.
The loss of IgG2a and 2b autoantibodies in TLR9-defi  cient 
mice was restricted to anti-self antibodies
The eff  ect of TLR9 defi  ciency on the reduction of IgG2a 
and 2b antibodies was restricted to autoantibodies because 
the number of plasma cells (CD138+) in spleen and bone 
marrow and the total serum level of all IgG subclasses were 
not reduced in 56R+FcγRIIB−/−TLR9−/−.B6 mice com-
pared with 56R+FcγRIIB−/−TLR9+/+ and +/−.B6 mice 
(Fig. 7 A and not depicted). Furthermore, the specifi  c IgG 
subclass response to NP-CGG (T-dependent) or NP-Ficoll 
(T-independent) immunization was not reduced in TLR9−/−.
B6 mice compared with TLR9+/−.B6 mice (Fig. 7 B).
Figure 4.  Loss of IgG2a and 2b autoantibodies in MyD88-defi  cient 
mice was B cell intrinsic. Naive splenic B cells from the indicated geno-
types were stimulated with 15 μg/ml CpG1826, 10 μg/ml anti-CD40, and 
10 ng/ml rmIL-4 in vitro for 5 d and total Ig subclass concentrations in 
the supernatants were determined. Class switching to IgM was un-
changed and to IgG1 increased in MyD88-defi  cient backgrounds. In con-
trast, switching to IgG2a, 2b, and 3 was signifi  cantly impaired.558  TLR/MYD88 REQUIREMENT FOR PATHOGENIC IGG2 IN MURINE SLE | Ehlers et al.
D  I  S  C  U  S  S  I  O  N 
The TLR9–MyD88 pathway is required for the generation 
of pathogenic anti-DNA/polyreactive autoantibodies of the 
IgG2a and 2b subclasses in vivo, based on the analysis of the 
spontaneous SLE models described in this study. These sub-
classes effi   ciently trigger infl  ammatory responses by their abil-
ity to preferentially engage the activation receptor FcγRIV 
on macrophages (20). This skewing of autoantibody responses 
through the TLR9–MyD88 pathway promotes class switch-
ing to these pathogenic subclasses and provides an explana-
tion for the predominance and pathogenicity of those 
antibodies in vivo. In the absence of TLR9, IgG2a and 2b 
autoantibodies were nearly as strongly reduced as in MyD88-
defi  cient mice, suggesting that TLR9 is the main MyD88-
dependent inducer of IgG2a and 2b autoantibodies in our 
lupus-prone mice (Fig. 5). However, activation of other 
TLRs may be partly involved as described previously (15).
No changes in the accumulation of IgG1 autoantibodies 
were observed in mice defi  cient in either MyD88 or TLR9. 
The fact that the number of IgG1-positive GCs or splenic 
plasma cells, which retained the intact 56R VDJ4 heavy 
chain, was not increased in 56R+RIIB−/−TLR9−/− mice as 
compared with 56R+RIIB−/− mice, argues against an IgG1 
default pathway in TLR9-defi  cient mice that could com-
pensate for the loss of IgG2a and 2b autoantibodies (unpub-
lished data).
Recently, the role of TLR9 in SLE was investigated by 
generating F2 crosses of TLR9−/− mice (on a mixed genetic 
background containing both B6 and 129Sv genomes) and 
Fas-defi  cient MRL/Mplpr/lpr mice (14). Consistent with our 
results, this TLR9 defi  ciency abrogated anti-DNA anti-
bodies; however, in contrast with our study, other autoanti-
bodies persisted and the animals were not protected from 
disease. These diff  erences most likely result from the diff  er-
ential contributions of genetic background to autoimmunity 
and disease progression in the mixed MRL/B6/129 back-
ground, thus accounting for the incomplete penetrance ob-
served in those studies. We further suggest that the increased 
escape of polyreactive B cells from central tolerance we ob-
served in FcγRIIB−/−.B6 mice (Figs. 3 and 5 and reference 6) 
more closely resembles the phenotype seen in pediatric SLE 
patients (16, 17) than the Fas-defi  cient phenotype, where a 
broadly based number of specifi  c self-reactive B and T cells 
are activated and protected from death in the periphery. The 
activation of the immune system in Fas-defi  cient  mice 
  probably depends to a greater extent on other MyD88 
  costimulators such as IL-1, IL-18, and other TLRs (27) than 
on TLR9.
Figure 5.  The TLR9 pathway was required for generation of IgG2a 
and 2b anti-DNA/polyreactive autoantibodies. IgG subclass analysis 
of autoantibodies in the serum of 7–11-wk-old 56R+RIIB−/−TLR9+/+.B6 
(n = 7), 56R+RIIB−/−TLR9+/−.B6 (n = 19), 56R+RIIB−/−TLR9−/−.B6 (n = 7), 
or 56R+RIIB−/−MyD88−/−.B6 (n = 6) mice as determined by ANA (A), 
anti-DNA (B), antiglomerular basement membrane (anti-GBM) (C), and 
anticardiolipin (D) ELISA, indicated a reduction of the autoreactive IgG2aa 
and IgG2b subclasses for both genotypes (P = 0.007 and P = 0.03, re-
spectively, for the ANA ELISA). (E) Polyreactivity was analyzed by preab-
sorbing the samples on the indicated ELISA plates; G: GBM; C: cardiolipin; 
G,C: GBM + cardiolipin. (F) TLR9-defi  cient IgMa
+ naive splenic B cells 
retained the intact 56R VDJ4H transgene, whereas IgG2a and 2b positive 
TLR9-defi  cient GC and splenic plasma cells did not use the intact 56R 
VDJ4H transgene (compare with Fig. 3).JEM VOL. 203, March 20, 2006  559
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A likely mechanism by which TLR9 signaling can break 
tolerance and promote specifi  c class switching to IgG2a and 
2b is suggested by the in vitro induction of the transcription 
factor T-bet by CpG DNA through the TLR9–MyD88 
pathway in B cells (Fig. 6 B and references 3, 24). Our results 
are thus consistent with the observation that T-bet defi  ciency 
results in decreased IgG2a, 2b, and 3 levels in the lupus-sus-
ceptible strain MLR/lpr (26). However, in contrast with our 
results, IgG1 levels are increased in MRL/lpr mice defi  cient 
in T-bet (26). This diff  erence could refl  ect the diff  erences in 
the mouse models used in the two studies.
Our data thus suggest a model (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20052438/DC1) 
in which anti-DNA/polyreactive naive IgM+ B cells that 
have escaped central tolerance can be induced to switch 
to the pathogenic IgG2a and 2b subclasses by stimulation 
of the TLR9–MyD88 pathway. This stimulation may 
  occur through pathogen-derived or apoptotic DNA delivered
to the endosomal TLR9 molecule by the anti-DNA B cell 
receptor (28), thus triggering TLR9/MyD88-dependent 
induction of T-bet expression and subsequent switching 
to IgG2a and 2b. These pathogenic subclasses are normally 
prevented from accumulation by the action of the inhibi-
tory receptor FcγRIIB, which limits the expansion of plasma 
cells and secretion of autoreactive IgGs (6). The reduction 
of FcγRIIB in other autoimmune-susceptible strains (7, 29–
32) removes this checkpoint and allows for the expansion of 
plasma cells secreting these pathogenic subclasses. Deposition 
of immune complexes results in tissue pathology and prema-
ture mortality that occurs through engagement of FcγRIV 
expressed on myeloid eff  ector cells (20). The identifi  cation 
of the TLR9–MyD88 pathway as a critical pathway in de-
termining the development of pathogenic polyreactive au-
toantibody subclasses in vivo provides the rationale for its 
targeting in disease like SLE.
MATERIALS AND METHODS
Mice. MyD88−/− and TLR9−/− mice were provided by S. Akira (Osaka 
University, Osaka, Japan) (27, 33) and backcrossed >12 and 9 generations, 
respectively, onto the C57BL/6 background. The 56R knockin mouse that 
is transgenic for an anti-DNA B cell receptor heavy (H) chain has been de-
scribed previously (6, 22, 23) (Fig. 3 C). MyD88−/− and TLR9−/− mice 
were crossed to FcγRIIB−/− or 56R+FcγRIIB−/− mice on a C57BL/6 
background to produce FcγRIIB−/−MyD+/−, FcγRIIB−/−MyD−/−, 
56R+FcγRIIB−/−MyD+/−, 56R+FcγRIIB−/−MyD−/−, 56R+FcγRIIB−/−
TLR9+/+, 56R+FcγRIIB−/−TLR9+/−, and 56R+FcγRIIB−/−TLR9−/− 
mice. Littermates were used as controls in each experiment. C57BL/6 mice 
were purchased from The Jackson Laboratory. All experiments were done 
in compliance with federal laws and institutional guidelines and have been 
Figure 6.  Loss of IgG2a and 2b autoantibodies in TLR9-defi  cient 
mice was B cell autonomous. (A) Naive splenic B cells from the indi-
cated genotypes were stimulated with 15 μg/ml CpG1826, 10 μg/ml 
anti-CD40, and 10 ng/ml rmIL-4 in vitro for 5 d and total Ig subclass 
  concentrations in the supernatants were determined. Class switching to 
IgM was unchanged and to IgG1 increased in TLR9-defi  cient backgrounds. 
In contrast, switching to IgG2a, 2b, and 3 was signifi  cantly impaired. 
(B) T-bet mRNA is not induced by CpG stimulation of B cells in the TLR9-
defi  cient background. A portion of the cells in (A) were collected after 12 h 
of the indicated stimulation. mRNA and cDNA were prepared and used for 
real-time PCR with specifi  c primers for T-bet and β-actin as an internal 
control. The ratio between TLR9-suffi  cient and -defi  cient B cells for T-bet 
mRNA was calculated after normalizing for β-actin. nd, not detected. 
Results from three independent experiments are shown as mean ± SD.
Figure 7.  Loss of IgG2a and 2b autoantibodies in TLR9-defi  cient 
mice was restricted to anti-self antibodies. (A) Analysis of total anti-
body isotypes and subclasses in the serum of 7–11-wk-old 56R+RIIB−/−
TLR9+/+.B6 (n = 7), 56R+RIIB−/−TLR9+/−.B6 (n = 19), or 56R+RIIB−/−
TLR9−/−.B6 (n = 7) mice as determined by ELISA. Horizontal bars repre-
sent the average. (B) The specifi  c IgG subclass responses to NP(24)-CGG 
or NP(24)-Ficoll immunization were not reduced in TLR9−/−.B6 mice com-
pared with TLR9+/−.B6 mice. The indicated anti-NP IgM and IgG sub-
classes were analyzed on day 11 after injection. Results from three 
independent experiments are shown as mean ± SD.560  TLR/MYD88 REQUIREMENT FOR PATHOGENIC IGG2 IN MURINE SLE | Ehlers et al.
  approved by The Rockefeller University. Genotypes were determined by 
PCR on tail DNA (Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20052438/DC1). All mice were fed with antibiotic (Sulfatrim) food 
to reduce the infl  uence of infections.
NP-cgg and NP-Ficoll immunization. 100 μg of NP(24)-cgg or 
NP(24)-Ficoll (Biosearch Technologies) were injected i.p. and IgM and IgG 
subclass titers were analyzed on day 11.
ELISA. For total immunoglobulin isotype and subclass determination, 
Nunc-Immuno 96-well MicroWell Maxisorp ELISA plates (Nalgene Nunc 
International) were coated overnight with goat anti–mouse IgG, IgM, IgA, 
IgE, IgG1, IgG2a, IgG2b, or IgG3 (Bethyl Laboratories) at a concentration 
of 10 μg/ml. After blocking with 50 mM Tris, pH 8, 0.14 M NaCl, 1% BSA 
for 30 min, 100 μl of 1/100 diluted serum or cell culture supernatant was 
applied for 1 h at room temperature. Captured antibodies were detected 
with horseradish peroxidase–coupled goat anti–mouse IgG, IgM, IgA, IgE, 
IgG1, IgG2a, IgG2b, and IgG3 (Bethyl Laboratories), followed by incuba-
tion with 3,3′,5,5′-tetramethylbenzidine peroxidase substrate solution. Ab-
sorbance was measured at 450 nm.
Detection of antibodies specifi  c for double-stranded DNA was done as 
described previously (6). In brief, ELISA plates were precoated with 5 μg/ml 
of methylated BSA (Sigma-Aldrich) followed by incubation overnight at 
4°C with 50 μg/ml of calf thymus DNA (Sigma-Aldrich). After washing, 
the plates were blocked (PBS, 3% BSA, 1 mM EDTA, 0.1% gelatin) and 
subsequently incubated with 1/100 diluted serum. Bound antibodies were 
detected as described for the immunoglobulin isotype and subclass determi-
nation. IgG2a autoantibodies of 56R+ B cells (haplotype: a) were detected 
with an antibody against IgG2aa (Bethyl Laboratories) and IgG2a antibodies 
of B cells without 56R+ (haplotype: b) were detected with an antibody 
against IgG2ab (Bethyl Laboratories). Antibodies against nuclear proteins and 
DNA were detected with an ANA ELISA kit (Corgenix) and antibodies 
against GBM and cardiolipin were detected with kits from Hycor, according 
to the manufacturer’s directions. Serum was diluted 1/100. Antibodies 
against NP were detected with NP(24)-BSA coated ELISA plates. Serum 
was diluted 1/300.
Kidney pathology. Kidneys were fi  xed with 10% formalin in PBS and 
embedded in paraffi   n. Paraffi   n-embedded sections were stained with hema-
toxylin and eosin. To assay for immune complex deposition and macrophage 
accumulation, kidneys were embedded in Tissue-Tek OCT compound and 
snap frozen. Sections (5 μm) were air-dried, fi  xed with cold acetone, and 
stained with FITC-conjugated anti–mouse IgG subclass antibodies (anti-
IgG1 and IgG3, Sigma-Aldrich; IgG2 ab [recognizing the C57BL/6 IgG2a 
protein] and IgG2b, Bethyl Laboratories), biotin-conjugated anti–mouse 
FcγRIV (20), and Cy3-conjugated antibiotin (Sigma-Aldrich) or PE-conju-
gated anti–mouse Mac-I (Becton Dickinson).
Flow cytometry. The following antibodies from Beckon Dickinson were 
used: anti–mouse AA4.1-FITC, anti–mouse B220-allophycocyanin, anti–
mouse CD19-PE, anti–mouse IgMa-PE, anti–mouse CD21-FITC, anti–
mouse CD23-Pe, anti–mouse GL7-FITC, anti–mouse FAS-PE, anti–mouse 
CD138-PE, and anti–mouse CD3ε-FITC.
Single cell sorting, cDNA synthesis, and PCR. The single cell 
PCR methodology has been described previously (6). In brief, imma-
ture IgMa
+AA4.1+CD19int bone marrow cells (knockin allele: IgMa), 
IgMa
+CD19+B220+ splenocytes, FAS+GL7+ GC splenocytes, and CD-
138high plasma splenocytes from indicated mice were sorted by a FACS-
Vantage (Becton Dickinson) cell sorter into 96-well PCR plates. Cells were 
lysed and cDNA was prepared as described. Transcripts were amplifi  ed by 
two rounds of PCR (outer and inner primers; Fig. S3) with the following 
conditions: denaturating for 5 min at 94°C, 50 cycles of 30 s at 94°C, 30 s 
at 60°C, 55 s (fi  rst PCR) or 45 s (second PCR) at 72°C, followed by fi  nal 
elongation for 10 min at 72°C.
In vitro stimulation. Naive B cells were enriched by the MACS B cell de-
pletion kit (Miltenyi Biotec). The purity was verifi  ed by FACS analyses and 
found to be >97% B cells. The cells were cultured for 5 d in RPMI 1610, 
10% FCS, 150 μg/ml streptomycin, 150 U/ml penicillin, and 5 μM 2-mer-
captoethanol with the indicated concentrations of rmIL-4 (PeproTech), 
anti-CD40 (Becton Dickinson), and CpG1823 (InvivoGen). Supernatants 
were used for ELISA analyses and RNA for RT-PCR was prepared with the 
RNeasy Mini kit (QIAGEN).
RT-PCR. cDNA was prepared with the superscript III polymerase kit 
  (Invitrogen). RT-PCR was performed with the SYBR green PCR Master 
Mix and the Applied Biosystems machine with the primers in Fig. S3.
Online supplemental material. Fig. S1 shows B cell development of 
MyD88-suffi   cient and -defi  cient mice characterized by FACS analyses. Fig. S2 
represents a model depicted the B cell checkpoints involved in the generation 
of anti-DNA/polyreactive autoantibodies and systemic autoimmune disease. 
Fig. S3 lists the primers used for the paper. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20052438/DC1.
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